+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

A

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the effectiveness of a group-based Acceptance and Commitment Therapy ACT intervention in reducing psychological distress and enhancing quality of life in family caregivers of stroke survivors. It focuses on whether this group intervention can improve psychological flexibility and reduce experiential avoidance, which may influence caregiver outcomes. The study uses a quasi-experimental design comparing participants who receive the intervention with those who do not initially. Participants in the experimental group will attend a 5-week program consisting of weekly 1.5-hour group sessions based on the ACT model. The control group will not receive the intervention during this period but will complete the same assessments. After the experimental group finishes, the control group will then receive the same ACT intervention. Study measures will be collected before treatment, immediately after, and at a 2-month follow-up. During the study, participants will complete questionnaires assessing psychological flexibility, quality of life, experiential avoidance, and caregiver strain at three time points. The study monitors caregiver psychological distress and quality of life over time to determine if the ACT group intervention provides benefits. Participation involves regular group sessions and completing standardized assessments, with the entire study extending through initial treatment and follow-up periods.

Age: 40Years +All GendersPhase Not Applicable
1 location
R

Actively Recruiting

This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.

Age: 18Years +All GendersPhase 3
285 locations